Nutriband Inc. (NASDAQ: NTRB) had a significant increase in stock performance as of today’s most recent check, with shares rising 20.64% to trade at $9.68. Following the company’s announcement of a 25% preferred stock dividend, investors are responding favorably to the rising momentum, which indicates strategic changes.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
Declaration of Preferred Stock Dividend
A 25% preferred stock dividend has been duly approved and announced by Nutriband’s Board of Directors. The business claims that for every four common shares owned, stockholders listed on file as of July 25, 2025, will get one preferred share. This dividend’s distribution date has been set for August 5.
Each preferred share will be convertible into one common share following FDA approval of Nutriband’s flagship AVERSA Fentanyl product. Alternatively, unconverted preferred shares will carry an entitlement to an annual cash dividend, subject to the company’s profitability and board approval.
Commercial Milestones in Aversa Fentanyl Development
Nutriband emphasized its commitment to shareholder value, particularly as the company advances toward commercializing AVERSA Fentanyl. In partnership with Kindeva, a well-known contract development and manufacturing organization (CDMO) that specializes in drug-device combination products, Nutriband finished scaling up the commercial production process for Aversa Fentanyl in June.
This milestone demonstrates how Kindeva’s FDA-approved fentanyl patch production techniques and Nutriband’s AVERSA technology are technically compatible.
Route to Regulatory Acceptance
An important advancement in opioid safety is the Aversa Fentanyl patch, which was created at Kindeva’s state-of-the-art transdermal manufacturing facility in the United States. In order to start human abuse liability trials, Nutriband must next produce clinical supplies and file an Investigational New Drug (IND) application to the FDA. The business would go closer to submitting a New Drug Application (NDA) if the IND approval was successful.
Innovative Technology to Prevent Abuse
In order to lessen abuse, distraction, and unintentional exposure to high-risk medications including opioids and stimulants, the AVERSA technology platform incorporates unpleasant chemicals into transdermal patches. While guaranteeing access for authorized patients, Aversa Fentanyl has the potential to transform opioid safety standards by becoming the first pain patch on the market that deters misuse.
